Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Pharmaceutical Planning, Portfolio, Technical Bio-Analysis and Licensing Consultant

Technical Consultant #2226


  • Pharmaceutical and biotechnology business development and new product planning.
  • In and Out licensing and strategic partnering.
  • Commercial analysis and forecasting.
  • Pharmaceutical life cycle management.
  • Start-up of Pharmaceuticals, business building in proprietary, generic, and OTC pharmaceuticals and biotechnology, providing modeling and commercial assessments.


Undisclosed Company, Chief Consultant, 2014 - Present

  • Prepared for pharmaceutical start-up forecast models and commercial assessments for a wide range of potential indications.
  • Placed clinical trial bio specimens with two companies for biomarker developments.
  • Developed for emerging biotechnology company: investor and sales presentations, business plan, product brochure, booth design, application briefs and press release for a new product launch.

SPI Pharma, Wilmington, DE, New Product Development and Project Management, 2012 - 2014

  • Developed Business Plans, introduced project evaluation and planning methods.
  • Managed projects and products, identified and evaluated new opportunities.

Salutria Pharmaceuticals, (Atherogenics, Inc.), Alpharetta, GA, 2004 - 2010

Senior Director Business Development

  • Spearheaded new product planning, forecasting, financial analysis, portfolio augmentation, biomarker development, and supply chain creation; helped plan and edit clinical protocols.
  • Held multiple business development roles in an emerging pharmaceutical company.
  • Completed with team members a $1billion deal with a major global pharmaceutical company.
  • Searched, found, justified, and took to term sheets and contracts several multi-national cardiovascular and metabolic disease in-licensing opportunities

aaiPharma, Senior Director Business Development, 2002 - 2004

  • Held broad business development responsibilities in a contract research organization transitioning to an integrated pharmaceutical company.
  • Generated product life cycle analyses for internal & external clients using drug delivery technologies, physical chemistry techniques, regulatory alternatives, and exclusivity strategies.
  • Played key role in new product planning for a Japanese joint venture conducting NCE development.

DuPont Merck Pharmaceuticals, 1985 - 2002

Senior Director Business Development and Strategic Planning

  • Responsible for global cardiovascular new product planning, licensing, and portfolio management.
  • Implemented innovative market development plan for a new antithrombotic drug.
  • Improved business intelligence and commercial support for research and development to ensure competitiveness.
  • Led negotiations and managed due diligence for major late-stage compound; also negotiated favorable terms while surmounting cultural barriers, complex CMC, and exclusivity issues.
  • Developed opportunity identification process and analyzed over 100 in-licensing candidates.

Director Product Planning

  • Key member of the Sustiva commercialization team responsible for the "best ever" HIV/AIDS drug launch.
  • Motivated team to improve forecasts using novel techniques: forecast came within a few percent of actual sales.
  • Analyzed pricing to find an optimal price that maximized sales without alienating customers.
  • Organized and built confidence in competent but inexperienced Launch Logistics Team.
  • Met urgent need for lifesaving drug by shipping largest dollar value in shortest time, by far, of any previous HIV drug - earned corporate and department Marketing Excellence Awards.

Endo Labs, LLC, Director Global Business Development

  • Responsible for strategic planning and new product generation for generic drug subsidiary.
  • Created Endo strategic plan: Basis for successful spinout of publicly-traded company with current market cap over $4 billion.
  • Identified opportunity and negotiated co-development agreement for major pain management product - Opana ER (oxymorphone HCl).
  • Invented and co-wrote patent, claiming a Product Life Cycle Management Invention.
  • Structured and negotiated agreements, expanded product line, developed essential customer relationships, and increased revenues - earned DuPont Pharmaceuticals' Summit Award.

Associate Director Business Development

  • Responsible for planning, licensing and business development.
  • Co-wrote business plan, structured, and negotiated international generic drug joint venture.
  • Structured, wrote, and negotiated supply, distribution, and joint development agreements with U.S. and foreign companies that helped establish generic drug business.

Associate Director New Product Planning

  • Managed portfolio evaluation process and created new product plans.
  • Created "JiffeVal", an artificial intelligence financial analysis Excel spreadsheet to facilitate financial analyses of pipeline products and in-licensing candidates.
  • Wrote new product plan convincing management to develop the first angiotensin receptor blocker - accurately forecast Cozaar/Hyzaar worldwide sales peak at $2.5 billion.

Senior Business Analyst

  • Provided financial analysis and deal-structuring services to medical products licensing group.
  • Developed novel epidemiology model to estimate market potential for early HIV/AIDS drug.

DuPont, Pigments, Chemicals, and Agricultural Products Departments, 1974 - 1985

Positions Held (of increasing complexity and responsibility)

  • Business Analyst: Analyzed capital projects and contracts.
  • Distribution Manager: Managed sales order center distribution group.
  • Production Supervisor: Supervised pigments manufacturing crew.
  • Technical Services Chemist: Handled customer complaints and new product development.

Honors & Publications


  • DuPont Corporate Marketing Excellence Award
  • DuPont Medical Products Department Summit Award


  • U.S. - Manufacturing Paroxetine
  • U.S. - Treating Retinal Diseases


  • M.B.A. University of Delaware, Newark, DE
  • M.B.A. Drexel University, Philadelphia, PA
  • B.A. Chemistry, Bryn Mawr College, Bryn Mawr, PA
Back to Search Result GO